{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/management/severe-infection/","result":{"pageContext":{"chapter":{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection","depth":2,"htmlHeader":"<!-- begin field 7338e40e-d250-4b86-80eb-83190f07936d --><h2>Scenario: Severe infection</h2><!-- end field 7338e40e-d250-4b86-80eb-83190f07936d -->","summary":"Covers the management of women presenting with severe vulvovaginal candidiasis (characterized by extensive vulvar erythema, oedema, excoriation, and fissure formation).","htmlStringContent":"<!-- begin item 40d60abe-adae-4922-a3d4-1c5b1dfa3961 --><!-- begin field cf1b9637-8c45-40d0-a8c5-acbc0156a9c5 --><p>From age 12 years onwards (Female).</p><!-- end field cf1b9637-8c45-40d0-a8c5-acbc0156a9c5 --><!-- end item 40d60abe-adae-4922-a3d4-1c5b1dfa3961 -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"a4128ab5-7d34-5cec-bd03-549dd2ed4353","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field e2f1c575-fc57-4758-b8a5-b2cfe38ce034 --><h3>How should I manage severe vulvovaginal candidiasis?</h3><!-- end field e2f1c575-fc57-4758-b8a5-b2cfe38ce034 -->","summary":null,"htmlStringContent":"<!-- begin item 56222673-8e43-4952-b733-864bf2966564 --><!-- begin field 79a8708e-bd7d-4d7d-acda-19bc7570b0d9 --><p><strong>To manage <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/background-information/definition/\">severe vulvovaginal candidiasis</a>:</strong></p><ul><li><strong>Send a vaginal specimen for microscopy, culture, and sensitivity, </strong>if appropriate. This may identify:<ul><li>A moderate/heavy growth of <em>Candida albicans</em>.</li><li>Non-albicans <em>Candida </em>species.</li><li>A <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">mixed infection</a>.</li></ul></li><li><strong>Prescribe antifungal treatment.</strong><ul><li>The choice of treatment and formulation will depend on factors such as contraindications and cautions, the licenced age and indication for the product, and the person's preference.<ul><li><strong>For most women, </strong>prescribe two doses of oral fluconazole 150 mg (to be taken 3 days apart). If oral treatment is contraindicated or unsuitable, prescribe two doses of clotrimazole vaginal pessaries 500 mg (to be used 3 days apart).</li><li><strong>For women aged 60 years and older,</strong> oral antifungals may be more acceptable because of the ease of administration.</li><li><strong>For girls </strong><strong>aged 12–15 years</strong><strong>, </strong>refer or seek specialist advice.</li><li><strong>For breastfeeding women, </strong>prescribe two doses of clotrimazole vaginal pessaries 500 mg (to be used 3 days apart).</li></ul></li><li><strong>If there are vulval symptoms,</strong> consider prescribing a topical imidazole in addition to an oral or intravaginal antifungal. Options include:<ul><li>Clotrimazole 1% or 2% cream applied 2–3 times a day.</li><li>Ketoconazole 2% cream applied 1–2 times a day (for adults aged 18 years and older).</li></ul></li><li><strong>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/\">Prescribing information</a> for detailed information on</strong> intravaginal, oral, and topical antifungals, including information on contraindications and cautions, adverse effects, and drug interactions.</li><li><strong>Be aware that</strong> intravaginal clotrimazole, oral fluconazole, and topical clotrimazole can be purchased over-the-counter.</li></ul></li><li><strong>Advise the woman:</strong><ul><li>To return if symptoms have not resolved within 7–14 days. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/severe-infection/#managing-treatment-failure\">Managing&nbsp;treatment failure</a> for more information.</li><li>On measures to aid symptom relief and prevent recurrence. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/severe-infection/#general-advice-on-self-management\">Self-management advice</a> for more information. </li></ul></li><li><strong>Follow-up and test of cure are <em>not</em> necessary if symptoms resolve.</strong></li><li><strong>Do not routinely treat </strong><strong>an asymptomatic sexual partner.</strong><ul><li>If the male partner of a woman with vulvovaginal candidiasis has balanitis (characterized by erythematous areas on the glans of the penis, pruritus, and/or irritation), see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/balanitis/\">Balanitis</a> for management information.</li></ul></li></ul><!-- end field 79a8708e-bd7d-4d7d-acda-19bc7570b0d9 --><!-- end item 56222673-8e43-4952-b733-864bf2966564 -->","subChapters":[{"id":"3a181e65-ef4b-549f-987a-64866d7c910f","slug":"basis-for-recommendation-146","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8f67addf-a91d-4073-86f0-e07ebea1baa7 --><h4>Basis for recommendation</h4><!-- end field 8f67addf-a91d-4073-86f0-e07ebea1baa7 -->","summary":null,"htmlStringContent":"<!-- begin item 146266f7-1be8-44c5-a897-06dd218fd4c8 --><!-- begin field 2f8d469f-10a4-4d5e-bf93-70a4b72e11b6 --><h5>Confirming the diagnosis</h5><ul><li>This recommendation is based on expert opinion in UK and US guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2006b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which differ in their recommendations for laboratory tests for women with vulvovaginal candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/#basis-for-recommendation-179\">Investigations</a> for more information.</li></ul><h5>Antifungal treatment</h5><ul><li><strong>Choice of antifungal treatment</strong><ul><li>For the treatment of severe vulvovaginal candidiasis:<ul><li>The British Society of Sexual Health and HIV (BASHH) <em>Guideline on the Management of Vulvovaginal Candidiasis</em> recommends treatment with 150 mg of oral fluconazole (repeated after 3 days) or, if oral fluconazole is contraindicated, a single dose of an antifungal intravaginal pessary (repeated after 3 days) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li><li>The US Centers for Disease Control and Prevention (CDC) recommends either a 7–14 day course of a topical imidazole or two doses of oral fluconazole 150 mg (taken 72 hours apart) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. However, expert opinion in the BASHH guideline is that because there is no evidence that 7 days of topical treatment is any more effective than a single dose of an oral azole, it is more logical to repeat the single dose after 3 days than to give local treatment for 14 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li></ul></li></ul></li><li><strong>Managing women aged 60 years and older</strong><ul><li><p>This recommendation is based on expert opinion in a review article, which states that after alternative diagnoses have been excluded and risk factors removed (where possible), the investigation and treatment of vulvovaginal candidiasis in older women should be the same as for younger women. However, oral regimens are perhaps more acceptable because of the ease of administration and the avoidance of potentially messy creams and suppositories [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Nwokolo and Boag, 2000</a>].</p></li></ul></li><li><strong>Managing girls </strong><strong>aged 12–15 years</strong><ul><li>This recommendation is based on the fact that management decisions for this age group are not straightforward:<ul><li>Intravaginal antifungal pessaries and cream are not recommended for pre-pubertal girls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>].</li><li>The British National Formulary (BNF) for Children states that treatment with an external cream may be more appropriate in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>]. However, this may not be effective for managing severe symptoms.</li><li>Oral fluconazole is not licensed for treating vulvovaginal candidiasis in children younger than 16 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li><li>Oral itraconazole is not licensed for use in children (age not specified by the manufacturer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li></ul></li><li><strong>Managing breastfeeding women</strong><ul><li>CKS recommends intravaginal clotrimazole (as for non-lactating women) as there is extensive experience with its use.</li><li>The manufacturer of oral fluconazole advises that breastfeeding is not recommended after high-dose treatment with (or repeated use of) oral fluconazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li></ul></li><li><strong>Managing vulval symptoms</strong><ul><li>This recommendation is based on the BNF, which states that vaginal applications may be supplemented with a topical antifungal cream for vulvitis and to treat other superficial sites of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li></ul><h5>Follow-up and test of cure not necessary </h5><ul><li>In the expert opinion of the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US CDC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], follow up and test of cure are unnecessary unless symptoms are persistent or recurrent.</li></ul><h5>Advice</h5><ul><li>The recommendation to advise the person to return if symptoms have not resolved within 7–14 days is based on expert opinion in review articles, which states that treatment failure is considered to have occurred if symptoms do not resolve within 7–14 days of antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel et al, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Watson et al, 2002</a>].</li><li>The recommendation to advise on measures to aid symptom relief is based on what CKS considers to be good clinical practice.</li></ul><h5>Not routinely treating an asymptomatic sexual partner</h5><ul><li>In the expert opinion of BASHH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>]and the CDC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], uncomplicated vulvovaginal candidiasis is not usually acquired through sexual intercourse, and the available data do not support treating asymptomatic male partner of women with vulvovaginal candidiasis.</li><li>However, a small percentage of male partners will develop balanitis, and they should be managed appropriately [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li></ul><h5>Treatments not recommended</h5><ul><li><strong>Oral ketoconazole</strong> — due to the increased risk of liver damage associated with its use, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorization for oral ketoconazole. It should no longer be prescribed for the treatment of fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">MHRA, 2013a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">MHRA, 2013b</a>].</li></ul><!-- end field 2f8d469f-10a4-4d5e-bf93-70a4b72e11b6 --><!-- end item 146266f7-1be8-44c5-a897-06dd218fd4c8 -->","subChapters":[]}]},{"id":"157cdb36-faaa-5d7b-859b-f125ed651500","slug":"general-advice-on-self-management","fullItemName":"General advice on self-management","depth":3,"htmlHeader":"<!-- begin field 9fe3fffe-9368-46b3-9ba7-0260ada78a1f --><h3>What advice on self-management should I give?</h3><!-- end field 9fe3fffe-9368-46b3-9ba7-0260ada78a1f -->","summary":null,"htmlStringContent":"<!-- begin item 69320dd9-c1a5-4325-bb6a-7ae7058266d2 --><!-- begin field 81ed4d5a-de22-482a-b5dc-327d7faf81f3 --><ul><li><strong>Advise the woman to:</strong><ul><li>Avoid the following potential predisposing factors:<ul><li>Washing and cleaning the vulval area with soap or shower gels (including those containing perfume and antiseptics [such as tea tree oil]), wipes, and 'feminine hygiene' products.</li><li>Cleaning the vulval area more than once a day.</li><li>Washing underwear in biological washing powder and using fabric conditioners.</li><li>Vaginal douching.</li><li>Wearing tight-fitting and/or non-absorbent clothing.</li></ul></li><li>Wash the vulval area with a soap substitute — this should be used externally and not more than once a day.</li><li>Use a simple emollient to moisturise the vulval area.</li><li>Consider using probiotics (such as live yoghurts) orally or topically to relieve symptoms.  </li></ul></li></ul><!-- end field 81ed4d5a-de22-482a-b5dc-327d7faf81f3 --><!-- end item 69320dd9-c1a5-4325-bb6a-7ae7058266d2 -->","subChapters":[{"id":"885c4e2a-1143-5446-a77c-64d427c91539","slug":"basis-for-recommendation-828","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 333e7494-8b3d-47b4-85fd-ef700d4580fb --><h4>Basis for recommendation</h4><!-- end field 333e7494-8b3d-47b4-85fd-ef700d4580fb -->","summary":null,"htmlStringContent":"<!-- begin item 828f992c-4350-4b5f-9d94-25ef9dd0b74d --><!-- begin field be04cd65-94d9-4c85-ad86-8fbb6022ddaa --><h5>Avoiding potential predisposing factors</h5><ul><li>Expert opinion in UK guidelines is that local irritants (such as soaps, shower gels, and ‘feminine hygiene’ products) and tight fitting, synthetic clothing can predispose to (or exacerbate) symptomatic vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>], although the evidence for these is limited, conflicting, or absent.</li><li>Evidence from observational studies suggests that vaginal douching increases the risk of infection and other adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].</li></ul><h5>General care of the vaginal skin</h5><ul><li>The advice on the general care of vulval skin and the use of a simple emollient is based on expert advice in the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>The management of vulval skin disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCOG, 2011</a>].</li></ul><h5>Probiotics</h5><ul><li>The British Medical Journal (BMJ) Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any randomized controlled trials (RCTs) comparing yoghurt containing <em>Lactobacillus acidophilus </em>with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].<ul><li>One small RCT (n = 55) that compared oral <em>L acidophilus </em>with placebo at 1 month when given after a single dose of oral fluconazole (150 mg) found that oral <em>L acidophilus</em>:<ul><li>Decreased vaginal discharge compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 9/26 [35%] with placebo; P = 0.03).</li><li>Reduced the presence of yeast detected by culture compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 10/26 [39%] with placebo; P = 0.01).</li></ul></li><li>There was no evidence of serious harm, but one systematic review (which did not identify any suitable RCTs) stated that oral yoghurt may cause gastrointestinal disturbance in people with lactose intolerance.</li><li>The authors of the BMJ review concluded that the following should be considered:<ul><li>Applying yoghurt intravaginally may be embarrassing and uncomfortable for some women.</li><li>Although different yoghurts can be purchased, their compositions vary, and their effects may differ.</li><li>The effect of alterations in vaginal pH that may occur with intravaginal yoghurt use is unknown.</li></ul></li></ul></li><li>CKS recommends advising the woman to consider using probiotics because although there is no evidence that they are effective, there is no evidence of (or concerns about) serious adverse effects.</li></ul><h5>Tea tree oil</h5><ul><li>The BMJ Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any RCTs comparing intravaginal tea tree oil with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].<ul><li>One systematic review (which did not identify any suitable RCTs) stated that topical tea tree oil can cause skin irritation and a severe allergic rash.</li><li>One case report found that topical tea tree oil was associated with systemic hypersensitivity reaction.</li></ul></li><li>Expert opinion in the joint Faculty of Sexual and Reproductive Healthcare (FSRH) and the British Association of Sexual Health and HIV (BASHH) guideline <em>Management of vaginal discharge in non-genitourinary medicine settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>] and the joint Royal College of General Practitioners (RCGP) Sex, Drugs and HIV Task Group and BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>] is that there is currently insufficient evidence to recommend the use of tea tree oil in the management of vulvovaginal candidiasis.</li></ul><!-- end field be04cd65-94d9-4c85-ad86-8fbb6022ddaa --><!-- end item 828f992c-4350-4b5f-9d94-25ef9dd0b74d -->","subChapters":[]}]},{"id":"e283daef-7734-518e-aed6-d1a416e4943b","slug":"managing-treatment-failure","fullItemName":"Managing treatment failure","depth":3,"htmlHeader":"<!-- begin field 8d1141b4-75fd-4504-904b-7e855b819fef --><h3>How should I manage treatment failure following treatment for severe vulvovaginal candidiasis?</h3><!-- end field 8d1141b4-75fd-4504-904b-7e855b819fef -->","summary":null,"htmlStringContent":"<!-- begin item 80b666d7-25ab-422a-a75c-990eb7e96625 --><!-- begin field 189f2170-f287-4037-8bad-639697a652a1 --><ul><li><strong>If symptoms have not resolved within 7–14 days of initial treatment:</strong><ul><li><strong>Confirm that the <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/severe-infection/#initial-management\">initial treatment</a> was used as recommended.</strong><ul><li>Be aware that topical treatments can cause vulvovaginal irritation, which may be mistaken for treatment failure. </li></ul></li><li><strong>Reassess </strong><strong>for <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/background-information/risk-factors/\">predisposing factors&nbsp;</a></strong>and remove or control as far as possible.</li><li><strong>Consider<em> </em></strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">alternative diagnoses</a><em>. </em></strong>If appropriate:<ul><li>Send a vaginal specimen for microscopy, culture, and sensitivity. This may identify a moderate/heavy growth of <em>Candida albicans</em>, non-albicans <em>Candida </em>species, or a <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">mixed infection</a>.</li><li>Consider measuring vaginal pH (if possible) to assess the likelihood of symptoms being due to <em>Candida </em>(pH less than or equal to 4.5), bacterial vaginosis (pH above 4.5), or <em>Trichomonas vaginalis </em>(pH above 4.5).</li><li>Arrange other <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/\">investigations</a> as clinically indicated.</li></ul></li></ul></li><li><strong>Treat the infection.</strong><ul><li>If there has been a lack of compliance with the initial treatment formulation, prescribe the alternative formulation (for example, prescribe oral treatment if there has been poor compliance with intravaginal treatment). </li></ul></li><li><strong>Reinforce <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/severe-infection/#general-advice-on-self-management\">self-management advice</a>.</strong></li><li><strong>Refer or seek specialist advice (using clinical judgement) if:</strong><ul><li>The person is aged 12–15 years.</li><li>The woman is breastfeeding.</li><li>There is doubt about the diagnosis.</li><li>Symptoms are not improving and treatment failure is unexplained.</li><li>A non-albicans <em>Candida </em>species is identified.</li><li>Treatment fails again.</li></ul></li></ul><!-- end field 189f2170-f287-4037-8bad-639697a652a1 --><!-- end item 80b666d7-25ab-422a-a75c-990eb7e96625 -->","subChapters":[{"id":"2ae3df7f-4a53-5d25-a673-39161b7f2655","slug":"basis-for-recommendation-f9c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9e2b699a-e2e3-49d2-bc26-479ee2fae989 --><h4>Basis for recommendation</h4><!-- end field 9e2b699a-e2e3-49d2-bc26-479ee2fae989 -->","summary":null,"htmlStringContent":"<!-- begin item f9cae8f7-497c-415b-844e-a13c957344e1 --><!-- begin field b6a83e86-0343-4f58-9fe2-e671d129b03e --><p>CKS found no evidence or national guidelines specifically on treatment failure of severe vulvovaginal candidiasis. These recommendations are largely based on what CKS considers to be good clinical practice.</p><h5>Confirming compliance with initial management </h5><ul><li>CKS recommends considering compliance with initial management, as treatment failure is more likely if there is poor compliance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>].</li><li>Topical antifungals usually cause no systemic adverse effects, although local mild burning or irritation may occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering this in women with persisting symptoms.</li></ul><h5>Reassessing for predisposing factors</h5><ul><li>CKS recommends reassessing for predisposing factors, as treatment failure is more likely if there is continued exposure to predisposing factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>].</li></ul><h5>Considering alternative diagnoses</h5><ul><li>The symptoms of vulvovaginal candidiasis are non-specific and may occur in women with other conditions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering alternative diagnoses if there is treatment failure, as misdiagnosis is a common cause for treatment failure.</li><li>The recommendations to send a vaginal specimen for microscopy, culture, and sensitivity and to consider measuring vaginal pH (if possible) are extrapolated from expert opinion in UK and US guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2006b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which differ in their recommendations for laboratory tests for women with vulvovaginal candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/#basis-for-recommendation-179\">Investigations</a> for more information.</li></ul><h5>Treatment</h5><ul><li>The recommendation on how to manage poor compliance is based on what CKS considers to be good clinical practice.</li></ul><h5>Referral or seeking specialist advice</h5><ul><li>The recommendation to arrange referral or seek specialist advice for girls aged 12–15 years is based on the fact that management decisions for this age group are not straightforward:<ul><li>Intravaginal antifungal pessaries and cream are not recommended for pre-pubertal girls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>].</li><li>The British National Formulary (BNF) for Children states that treatment with an external cream may be more appropriate in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>]. However, this may not be effective for managing severe symptoms.</li><li>Oral fluconazole is not licensed for treating vulvovaginal candidiasis in children younger than 16 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li><li>Oral itraconazole is not licensed for use in children (age not specified by the manufacturer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li><li>The recommendation to arrange referral or seek specialist advice if the woman is breastfeeding is based on what CKS considers to be good clinical practice.<ul><li>The manufacturer advises that breastfeeding is not recommended after high-dose treatment with (or repeated use of) oral fluconazole, except for potentially life-threatening infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>], and itraconazole is not recommended for use in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li><li>The recommendation to arrange referral or seek specialist advice if non-albicans <em>Candida</em> species is identified is based on expert opinion in guidelines issued by the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US Centers for Disease Control and Prevention (CDC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which state that:<ul><li>The optimal treatment of non-albicans vulvovaginal candidiasis is currently unknown. Options include longer duration of treatment (7–14 days) with a non-fluconazole azole regimen (oral or topical) as first-line treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li><li>In some people with resistant organisms, treatments that should only be initiated by a specialist, or are difficult to obtain in primary care, may be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li></ul></li><li>The other recommendations on when to arrange referral or seek specialist advice are based on what CKS considers to be good clinical practice.</li></ul><!-- end field b6a83e86-0343-4f58-9fe2-e671d129b03e --><!-- end item f9cae8f7-497c-415b-844e-a13c957344e1 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}